[
    [
        {
            "time": "",
            "original_text": "舒泰神子公司拟千万美元参与复宏汉霖IPO",
            "features": {
                "keywords": [
                    "舒泰神",
                    "子公司",
                    "复宏汉霖",
                    "IPO",
                    "千万美元"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "舒泰神子公司拟千万美元参与复宏汉霖IPO",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药(02196.HK)向合营提供7088.3万元委托贷款",
            "features": {
                "keywords": [
                    "复星医药",
                    "合营",
                    "委托贷款",
                    "7088.3万元"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)向合营提供7088.3万元委托贷款",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药品性价比拼时代来袭，44药企研发投入超1亿元",
            "features": {
                "keywords": [
                    "药品",
                    "性价比",
                    "研发投入",
                    "44药企",
                    "1亿元"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药品性价比拼时代来袭，44药企研发投入超1亿元",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]